




Recombinant Human IL-18BP

Catalog#:P00416 Derived from Human Cells

DESCRIPTION	<p>Recombinant Human Interleukin-18-binding Protein is produced by our Mammalian expression system and the target gene encoding Thr31-Gly194 is expressed with a human IgG1 Fc tag at the C-terminus.</p> <p>Accession#: O95998</p> <p>Known as: Interleukin-18-binding protein; Tadekinig-alfa and IL18BP</p>																				
FORMULATION	Lyophilized from a 0.2 μ m filtered solution of PBS, pH 7.4.																				
SHIPPING	<p>The product is shipped at ambient temperature.</p> <p>Upon receipt, store it immediately at the temperature listed below.</p>																				
STORAGE	<p>Lyophilized protein should be stored at $\leq -20^{\circ}\text{C}$, stable for one year after receipt.</p> <p>Reconstituted protein solution can be stored at 2-8$^{\circ}\text{C}$ for 2-7 days.</p> <p>Aliquots of reconstituted samples are stable at $\leq -20^{\circ}\text{C}$ for 3 months.</p>																				
RECONSTITUTION	<p><i>Always centrifuge tubes before opening. Do not mix by vortex or pipetting.</i></p> <p><i>It is not recommended to reconstitute to a concentration less than 100$\mu\text{g}/\text{ml}$.</i></p> <p>Dissolve the lyophilized protein in distilled water.</p> <p>Please aliquot the reconstituted solution to minimize freeze-thaw cycles.</p>																				
QUALITY CONTROL	<p>Mol Mass:44.8kDa AP Mol Mass:60-75kDa, reducing conditions.</p> <p>Purity: Greater than 95% as determined by reducing SDS-PAGE.</p> <p>Endotoxin: Less than 0.1ng/μg (1 EU/μg) as determined by LAL test.</p>																				
BACKGROUND	<p>Interleukin-18-binding protein, also known as Tadekinig-alfa and IL18BP, contains 1 Ig-like C2-type domain. IL18BP is constitutively expressed and secreted in mononuclear cells. IL18BP functions as an IL18 inhibitor. IL18BP binds to IL18, prevents the binding of IL18 to its receptor, and thus inhibits IL18-induced IFN γ production. It has been shown that IL18BP may be a promising molecular approach to inhibit neointimal hyperplasia and arteriosclerosis progression following coronary and peripheral angioplasty.</p>																				
	<table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 30%;"></th> <th style="width: 10%; text-align: center;">kDa</th> <th style="width: 10%; text-align: center;">MK</th> <th style="width: 10%; text-align: center;">R</th> </tr> </thead> <tbody> <tr> <td></td> <td style="text-align: center;">120</td> <td colspan="2" rowspan="7" style="text-align: center; vertical-align: middle;">  </td> </tr> <tr> <td></td> <td style="text-align: center;">90</td> </tr> <tr> <td></td> <td style="text-align: center;">60</td> </tr> <tr> <td></td> <td style="text-align: center;">40</td> </tr> <tr> <td style="text-align: center;">SDS-PAGE</td> <td style="text-align: center;">30</td> </tr> <tr> <td></td> <td style="text-align: center;">20</td> </tr> <tr> <td></td> <td style="text-align: center;">14</td> </tr> </tbody> </table>		kDa	MK	R		120				90		60		40	SDS-PAGE	30		20		14
	kDa	MK	R																		
	120																				
	90																				
	60																				
	40																				
SDS-PAGE	30																				
	20																				
	14																				